References
1. Dhama K, Khan S, Tiwari R, et al. Coronavirus disease 2019-COVID-19.Clinical Microbiol Rev . 2020;33(4):e00028-20.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. Lancet .
2020;395(10223):497-506.
3. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and
mortality among black patients and white patients with COVID-19.New Engl J Med . 2020;382(28):2634-2543.
4. Kashyap S, Gombar S, Yadlowsky S, et al. Measure what matters: counts
of hospitalized patients are a better metric for health system capacity
planning for a reopening. J Am Med Inform Assoc .
2020;27(7):1026-1131.
5. Liu Y, Yang Y, Zhang C. Clinical and biochemical indexes for
2019-nCoV infected patients linked to viral load and lung
injury.Sci China Life Sci .2020;63:364-374.
6. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19
Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446.
7. Tabary M, Khanmohammadi S, Araghi F, et al. Pathologic features of
COVID-19: a concise review. Pathol Research &
Practice .2020;216:153097.
8. Batty CJ, Heise MT, Bachelder EM, et al. Vaccine formulation and
clinical development for the prevention of severe acute respiratory
syndrome coronavirus 2 infection. Adv Drug Del Reviews .
2021;169:168-189.
9. Reardon S. The most worrisome mutations in five emerging coronavirus
variants. Scientific American . 2021; 324: Epub Jan 29.
10. Callaway E, Mallopaty S. Novavax offer first evidence that COVID
vaccines protect people against variants. Nature. 2021;589:.Epub
Jan 29.
11. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody
LY-CoV555 in outpatients with Covid-19. New Engl J Med . 2021;
384(3):229-237.
12. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-CoV2, a
neutralizing antibody cocktails in outpacd, tients with Covid-19.New Engl J Med . 2021; 384(3):238-251.
13. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir
versus standard care on clinical status at 11 days in patients with
moderate COVID-19. JAMA. 2020; 324(11):1048-1057.
14. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone
on days alive and ventilator-free in patients with moderate or severe
acute respiratory distress syndrome and COVID-19. JAMA . 2020;
324(13):1307-1316.
15. Lemos ACB, do Espirito Santo DA, Salvetti MC, et al. Therapeutic
versus prophylactic anticoagluation for severe COVID-19. Thromb
Res . 2020; 196: 359-366.
16. Frankel AE,Reddy R, DeSouza KR, et al. Response to pegylated
interferon in a COVID-19 positive elderly woman with primary
myelofibrosis treated with ruxolitinib. Clinical Case Reports .
2021; in press.
17. Asa SL, La Rosa S, Basturk O, et al. Molecular pathology of
well-differentiated gastro-entero-pancreatic neuroendocrine tumors.Endocrine Pathol. 2021; Epub, Jan 18.
18. Gade AK, Olariu E, Douthit NT. Carcinoid syndrome. Cureus.2020; 12(3):e7186.
19. Oleinikov K, Avriel-Polak S, Gross DJ, et al. Carcinoid syndrome:
updates and review of current therapy. Curr Treat Options Oncol .
2019;20(9):70.
20. Strosberg JR, Weber JM, Feldman M, et al. Prognostic validity of the
American Joint Committee on Cancer Staging Classification for midgut
neuroendocrine tumors. J Clin Oncol . 2013;31(4):420-425.
21. Husain A, Byrareddy SN. Rapamycin as a potential repurposed drug
candidate for the treatment of COVID-19. Chem Biol Interact .
2020;331:109282.
22. Philippe L, van den Elzen AMG, Watson MJ, et al. Global analysis of
LARP1 translation targets reveal tunable and dynamic features of 5’-TOP
motifs. Proc Natl Acad Sci USA .2020; 117(10): 5319-5328.
23. Appelberg S, Gupta S, Akusjarvi SS, et al. Dysregulation of
Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of
SARS-CoV-2 infected cells. Emerg Microbes Infect .
2020;9(1):1748-1760.
24. Schmidt N, Lareau CA, Keshishan H, et al. The SARS-CoV-2 RNA protein
interactome in infected human cells. Nature Microbiol .2020;Epub
Dec21.
25. Rao S, Hoskins I, Garcia PD, et al. Genes with 5’-terminal
oligopyrimidine tracts preferentially escape global suppression of
translation by the SARS-CoV-2 Nsp1 protein. bioRxiv .2020;Epub,
Dec 18.
26. Toldo S, Bussani R, Nuzzi V, et al. Inflammasome formation in the
lungs of patients with fatal COVID-19. Inflammation Res.2021;70(1):7-10.
27. Freeman TL, Swartz TH. Targeting the NLRP3 inflammasome in severe
COVID-19. Front Immunol .2020;11:1518.
28. Wang H, Zhang P, Sun L. Exogeneous hydrogen sulfide inhibits NLRP3
inflammasome mediated inflammation through promoting autophagy via the
AMPK-mTOR pathway. Biol Open. 2019;8:bio043653.
29. Yang T, Feng X, Zhao Y, et al. Dexmedotamidine enhances autophagy
via alpha2-AR/AMPK/mTOR pathway to inhibit the activation of NLRP3
inflammasome and subsequently alleviate liposaccharide induced acute
kidney injury. Front Pharm. 2020;11:790.
30. Li X, Zhang X, Pan Y, et al. mTOR regulates NLRP3 inflammasome
activation via reactive oxygen species in murine lupus. Acta
Biochim Biophys Sin .2018;50(9):888-896.
31. Sa Ribero M, Jouvenet N, Dreux M, et al. Interplay between
SARS-CoV-2 and the type I interferon response. PLoS
Pathogens .2020;16(7):e1008737.
32. Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits
interleukin-1 production and inflammasome activation.Immunity .2011;34(2):213-223.
33. Ning X, Wang Y, Jing M, et al. Apoptotic caspases suppress type I
interferon production via the cleavage of cGAS, MAVS, and IRF3.Molecular Cell . 2019;74:19-31
34. Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or
suppress immune responses in COVID-19? Cytokine and anti-cytokine
interventions. Autoimmunity reviews. 2020;19(7):102567.
35. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in
adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol.2020;146(1):110-118.
36. Merad M, Martin JC. Pathological inflammation in patients with
COVID-19: a key role for monocytes and macrophages. Nat Rev
Immunol. 2020;20(6):355-362.
37. Devresse A, Belkhir L, Vo B, et al. COVID-19 infection in kidney
transplant recipients. Kidney Medicine. 2020;2(4):459-466.
38. Peron A, La Briola F, Bruschi F, et al. Tuberous sclerosis complex
(TSC), lymphangioleiomyo-matosis, and COVID-19. Am J Med Genet A .
2020;182(11):2479-2485.
39. Heron VC, Bach CAT, Holmes NE, et al. Complete recovery from
COVID-19 in a kidney-pancreas transplant recipient: potential benefit of
everolimus? BMJ Case Rep . 2021;14(1):e238413.
40. Colmenero J, Rodriguez-Peralvarez M, Salcedo M, et al.
Epidemiological pattern, inicidence, and outcomes of COVID-19 in liver
transplant patients. J Hepatol .2021;74(1):148-155.
41. Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV
viral load dynamics, duration of viral shedding and inectiousness: a
systematic review and meta-analysis. Lancet Microbe. 2020; Epub
Nov 19.
42. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of SARS-CoV-2
infectivity: when is it safe to discontinue isolation? Clin Infect
Dis . 2020;Epub Aug 25.
43. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2
from diagnostic samples. Clin Infect Dis . 2020;Epub May 22.
44. Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged
infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised
individual with cancer. Cell . 2020;Epub Nov 4.
45. Rodriguez-Grande C, Adan-Jimenez J, Catalan P, et al. Inference of
active viral replication in cases with sustained positive RT-PCRs from
SARS-CoV-2. J Clin Microbiol . 2020;Epub Nov 25.
46. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of
mTOR inhibition. Nat Rev Immunol .2009;9(5):324-337.
47. Kim MC, Cui C, Shin KR, et al. Duration of culturable SARS-CoV-2 in
hospitalized patients with Covid-19.New Engl J Med .
2021;384:Epub, Jan 27.
48. Bohn JP, Gastl G, Steurer M. Long term treatment of hairy cell
leukemia with interferon-alpha: still a viable therapeutic option.Memo . 2016;9:63-65.
49. Hasselbalch HC, Holmstrom MO. Perspectives on interferon-alpha in
the treatment of polycythemia vera and related myeloprolifeative
neoplasms: minimal residual disease and cure? Semin Immunopath .
2019;41(1):5-19.
50. Kanderli RM, Spanjol M, Kollar A, et al. Therapeutic options for
neuroendocrine tumors. JAMA Oncol .2019;5(4):480-489.
51. Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between
severe acute respiratory syndrome coronavirus 2 and host antiviral
defence: lessons from other pathogenic viruses. Emerging microbes
& infections. 2020;9(1):558-570.
52. Wang N, Zhan Y, Zhu L, e al. Retrospective multicenter cohort study
shows early interferon therapy is associated with favora ble clinical
responses in COVID-19 patients. Cell Host Microbe.2020;28(3):456-464.
53. Zhou Q, Chen V, Shannon CP, et al. Interferon-alpha2b treatment for
COVID-19. Front Immunol. 2020;11:1061.
54. Hung IFH, Lung KC, Tso EYK, et al. Triple combination of interferon
beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients
admitted to hospital with COVID-19: an open-label, randomised, phase 2
trial. Lancet . 2020;395(10238): 1695-1704.
55. Zheng F, Zhou Y, Zhou Z, et al. SARS-CoV-2 clearance in COVID-19
patients with Novaferon treatment: a randomized, open-label,
parallel-group trial. Int J Infect Dis . 2020;99:84-91.
56. Davoudi-Monfared E, Rahmani H, Hhalill H, et al. A randomized
clinical trial of the efficacy and safety of interferon beta-1a in
treatment of severe COVID-19. Antimicrob Agents Chemother.2020;64(9):e01061.
57. Pereda R, Gonzalez D, Rivero HB, et al. Therapeutic effetiveness of
interferon-alpha2b against COVID-19: the Cuban experience. J
Interferon Cytokine Res . 2020;40(9):438-442.
58. Fu W, Liu Y, Liu L, et al. An open-label, randomized trial of the
combination of IFN-kappa plus TFF2 with standard care in the treatment
of patients with moderate COVID-19. EClinicalMedicine . 2020;
27:100547.
59. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine
Storm’ in COVID-19. J Infect. 2020;80(6):607-613.
60. Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanism
of critical illness in Covid-19. Nature . 2020; Epub Dec 11.
61. Zheng Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN
immunity in patients with life-threatening COVID-19. Science .
2020;370(6515):eabd4570.
62. Bastard P, Rosen LB, Zheng Q, et al. Autoantibodies against type I
IFN in patients with life-threatening COVID-19. Science .
2020;370(6515):eabd4585.
Table 1. RT-PCR Cq values *